G17DT Completed Phase 2 Trials for Jaundice / Malignant Neoplasm of Pancreas Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02098291An Open, Single-center Study to Determine the Antibody Repsonse to Gastrimmune and Its Safety and Tolerability in Patients With Advanced Pancreatic Carcinoma
NCT02098239Single Centre Study to Determine the Antibody Response to G17DT in Patients With Advanced Pancreatic Cancer.